Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | GALR3 | O60755 | 1/20 | 0.36 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL711049 | 0.85 | HSP90AB1 (0.50) | POLBKMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL7278528 | 0.73 | NOS2 (0.41) | POLBGAALMNABACE1 | |
| SCHEMBL13596557 | 0.73 | CYP19A1 (0.50) | KMT2AMEN1DHFRBACE1 | |
| SCHEMBL1293068 | 0.72 | BCHE (0.39) | — | |
| SCHEMBL2411656 | 0.70 | MEN1 (0.58) | POLBKMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL7272832 | 0.70 | NOS2 (0.44) | — | |
| SCHEMBL5223298 | 0.69 | — | — | |
| SCHEMBL16255821 | 0.67 | — | — | |
| SCHEMBL1292950 | 0.67 | — | — | |
| SCHEMBL2135113 | 0.67 | TAAR1 (0.68) | GFERLMNATAAR1AOC3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428061-B2 | Autotaxin inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
| EP-3253748-B1 | AUTOTAXIN INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2019-04-17 | — | — | EP | disclosed |
| US-20180022742-A1 | AUTOTAXIN INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20180022742-A1 | AUTOTAXIN INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| WO-2016124938-A1 | AUTOTAXIN INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022742-A1 | AUTOTAXIN INHIBITORS | ENPP2, RNASE1, ATXN10 | POLB 1170/4885KMT2A 353/4885MEN1 1121/4885 |
| US-10428061-B2 | Autotaxin inhibitors | ENPP2, ATXN10, RNASE1 | POLB 1016/4885KMT2A 248/4885MEN1 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.